AgeX Therapeutics (AGE) Sees Large Drop in Short Interest

AgeX Therapeutics (NYSE:AGE) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,122,420 shares, a decline of 10.3% from the December 14th total of 1,251,113 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average daily volume of 237,098 shares, the short-interest ratio is currently 4.7 days.

AGE stock opened at $4.67 on Friday. AgeX Therapeutics has a 1-year low of $1.13 and a 1-year high of $5.95.

TRADEMARK VIOLATION NOTICE: “AgeX Therapeutics (AGE) Sees Large Drop in Short Interest” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2019/01/11/agex-therapeutics-age-sees-large-drop-in-short-interest.html.

AgeX Therapeutics Company Profile

AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues.

Featured Article: Liquidity

Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply